Literature DB >> 29684595

Apelin and Elabela/Toddler; double ligands for APJ/Apelin receptor in heart development, physiology, and pathology.

Keiji Kuba1, Teruki Sato2, Yumiko Imai3, Tomokazu Yamaguchi4.   

Abstract

Apelin is an endogenous peptide ligand for the G protein-coupled receptor APJ/AGTRL1/APLNR and is widely expressed throughout human body. In adult hearts Apelin-APJ/Apelin receptor axis is potently inotropic, vasodilatory, and pro-angiogenic and thereby contributes to maintaining homeostasis in normal and pathological hearts. Apelin-APJ/Apelin receptor is also involved in heart development including endoderm differentiation, heart morphogenesis, and coronary vascular formation. APJ/Apelin receptor had been originally identified as an orphan receptor for its sequence similarity to Angiotensin II type 1 receptor, and it was later deorphanized by identification of Apelin in 1998. Both Apelin and Angiotensin II are substrates for Angiotensin converting enzyme 2 (ACE2), which degrades the peptides and thus negatively regulates their agonistic activities. Elabela/Toddler, which shares little sequence homology with Apelin, has been recently identified as a second endogenous APJ ligand. Elabela plays crucial roles in heart development and disease conditions presumably at time points or at areas of the heart different from Apelin. Apelin and Elabela seem to constitute a spatiotemporal double ligand system to control APJ/Apelin receptor signaling in the heart. These expanding knowledges of Apelin systems would further encourage therapeutic applications of Apelin, Elabela, or their synthetic derivatives for cardiovascular diseases.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  APJ; Angiotensin II; Angiotensin converting enzyme 2 (ACE2); Apela; Apelin; Aplnr; Beta-arreatin; Elabela; G protein; Toddler

Mesh:

Substances:

Year:  2018        PMID: 29684595     DOI: 10.1016/j.peptides.2018.04.011

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  18 in total

1.  Interaction of apelin, elabela and nitric oxide in schizophrenia patients.

Authors:  Zekiye Catak; Hilal Kaya; Esra Kocdemir; Kader Ugur; Guzel Saadet Pilten; Meltem Yardim; Ibrahim Sahin; Agirbas Esra Piril; Suleyman Aydin
Journal:  J Med Biochem       Date:  2020-01-23       Impact factor: 3.402

Review 2.  A new immunometabolic perspective of intervertebral disc degeneration.

Authors:  Vera Francisco; Jesús Pino; Miguel Ángel González-Gay; Francisca Lago; Jaro Karppinen; Osmo Tervonen; Ali Mobasheri; Oreste Gualillo
Journal:  Nat Rev Rheumatol       Date:  2021-11-29       Impact factor: 20.543

3.  ERK/HIF-1α/VEGF pathway: a molecular target of ELABELA (ELA) peptide for attenuating cardiac ischemia-reperfusion injury in rats by promoting angiogenesis.

Authors:  Kamran Rakhshan; Masoomeh Sharifi; Fatemeh Ramezani; Yaser Azizi; Nahid Aboutaleb
Journal:  Mol Biol Rep       Date:  2022-09-21       Impact factor: 2.742

4.  ELABELA antagonizes intrarenal renin-angiotensin system to lower blood pressure and protects against renal injury.

Authors:  Chuanming Xu; Fei Wang; Yanting Chen; Shiying Xie; Danielle Sng; Bruno Reversade; Tianxin Yang
Journal:  Am J Physiol Renal Physiol       Date:  2020-03-16

5.  Apelin-13 inhibits apoptosis and excessive autophagy in cerebral ischemia/reperfusion injury.

Authors:  Zi-Qi Shao; Shan-Shan Dou; Jun-Ge Zhu; Hui-Qing Wang; Chun-Mei Wang; Bao-Hua Cheng; Bo Bai
Journal:  Neural Regen Res       Date:  2021-06       Impact factor: 5.135

6.  Structure-guided discovery of a single-domain antibody agonist against human apelin receptor.

Authors:  Yanbin Ma; Yao Ding; Xianqiang Song; Xiaochuan Ma; Xun Li; Ning Zhang; Yunpeng Song; Yaping Sun; Yuqing Shen; Wenge Zhong; Liaoyuan A Hu; Yingli Ma; Mei-Yun Zhang
Journal:  Sci Adv       Date:  2020-01-15       Impact factor: 14.136

7.  Apelin+ Endothelial Niche Cells Control Hematopoiesis and Mediate Vascular Regeneration after Myeloablative Injury.

Authors:  Qi Chen; Yang Liu; Hyun-Woo Jeong; Martin Stehling; Van Vuong Dinh; Bin Zhou; Ralf H Adams
Journal:  Cell Stem Cell       Date:  2019-11-21       Impact factor: 24.633

8.  Apela improves cardiac and renal function in mice with acute myocardial infarction.

Authors:  Yang Pan; Quanyi Li; Hong Yan; Jin Huang; Zhi Wang
Journal:  J Cell Mol Med       Date:  2020-07-20       Impact factor: 5.310

Review 9.  International Union of Basic and Clinical Pharmacology. CVII. Structure and Pharmacology of the Apelin Receptor with a Recommendation that Elabela/Toddler Is a Second Endogenous Peptide Ligand.

Authors:  Cai Read; Duuamene Nyimanu; Thomas L Williams; David J Huggins; Petra Sulentic; Robyn G C Macrae; Peiran Yang; Robert C Glen; Janet J Maguire; Anthony P Davenport
Journal:  Pharmacol Rev       Date:  2019-10       Impact factor: 25.468

Review 10.  The role of Elabela in kidney disease.

Authors:  Qian Zheng; Geng Tian; Feng Xu; Xin Ci; Rumei Luan; Linlin Wu; Xuehong Lu
Journal:  Int Urol Nephrol       Date:  2021-03-08       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.